Algorae Pharmaceuticals Limited
LVCLF
$0.0063
$0.000916.67%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -855.60K | -1.12M | -1.37M | -1.43M | -1.49M |
| Total Depreciation and Amortization | -- | -- | -- | 200.00 | 400.00 |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 195.20K | 355.00K | 515.90K | 358.10K | 199.50K |
| Change in Net Operating Assets | -141.40K | -141.40K | -141.40K | -37.40K | 67.20K |
| Cash from Operations | -801.80K | -902.20K | -997.70K | -1.11M | -1.22M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 593.00K | 209.30K | -177.70K | -413.70K | -649.50K |
| Cash from Investing | 593.00K | 209.30K | -177.70K | -413.70K | -649.50K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 51.60K | 311.90K | 572.20K | 1.62M | 2.67M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -49.20K | -49.20K | -49.20K | -174.10K | -299.00K |
| Cash from Financing | 1.60K | 171.30K | 341.80K | 959.00K | 1.59M |
| Foreign Exchange rate Adjustments | -1.60K | -1.50K | -1.40K | 2.10K | 5.70K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -209.00K | -523.30K | -835.30K | -559.60K | -275.80K |